Idarubicin, Cytarabine and Pravastatin As Induction Therapy for Untreated Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

被引：1
|
作者：
Shadman, Mazyar [1 ,2 ]
Mawad, Raya [3 ]
Dean, Carol [1 ]
Shannon-Dorcy, Kathleen [1 ]
Sandhu, Vicky [1 ]
Hendrie, Paul C. [2 ]
Scott, Bart L. [1 ,2 ]
Walter, Roland B. [1 ,2 ]
Becker, Pamela S. [1 ,2 ]
Pagel, John [1 ,2 ]
Estey, Elihu H. [2 ]
机构：
[1] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[2] Univ Washington, Seattle, WA 98195 USA
[3] Swedish Med Ctr, Seattle, WA USA
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
10.1182/blood.V124.21.3732.3732
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Lenalidomide in High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia with Chromosome 5 Abnormalities
    Mollgard, Lars
    Nilsson, Lars
    Kjeldsen, Lars
    Dybedal, Ingunn
    Dufva, Inge Hogh
    Garelius, Hege
    Norgaard, Jan Maxwell
    Linder, Olle
    Ejerblad, Elisabeth
    Astermark, Jan
    Hellstrom-Lindberg, Eva
    BLOOD, 2009, 114 (22) : 52 - 52
  • [42] CYTARABINE PLUS IDARUBICIN AS INDUCTION THERAPY FOR UNTREATED ADULT PATIENTS WITH ACUTE MYELOID LEUKEMIA. A SINGLE CENTER RETROSPECTIVE ANALYSIS OF 141 PATIENTS
    Leite, L.
    Nunes, M.
    Chacim, S.
    Ferreira, I.
    Moreira, C.
    Pereira, D.
    Brito, M.
    Viterbo, L.
    Martins, A.
    Moreira, I.
    Domingues, N.
    Espirito-Santo, A.
    Oliveira, I.
    Mariz, J.
    HAEMATOLOGICA, 2013, 98 : 521 - 521
  • [43] Final update of phase I-II study of the farnesyltransferase inhibitor tipifarnib in combination with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
    Delmonte, John, Jr.
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    Estrov, Zeev
    Ravandi, Farhad
    Verstovsek, Srdan
    O'Brien, Susan
    Koller, Charles A.
    Faderl, Stefan
    Thomas, Deborah A.
    Wright, John J.
    Cortes, Jorge
    BLOOD, 2007, 110 (11) : 136A - 136A
  • [44] Patterns of lower risk myelodysplastic syndrome progression: factors predicting progression to high-risk myelodysplastic syndrome and acute myeloid leukemia
    Jain, Akriti G.
    Ball, Somedeb
    Aguirre, Luis
    Al Ali, Najla
    Kaldas, David
    Tinsley-Vance, Sara
    Kuykendall, Andrew
    Chan, Onyee
    Sweet, Kendra
    Lancet, Jeffrey E.
    Padron, Eric
    Sallman, David A.
    Komrokji, Rami
    REVISTA CHILENA DE LITERATURA, 2024, (109): : 2157 - 2164
  • [45] Patterns of lower risk myelodysplastic syndrome progression: factors predicting progression to high-risk myelodysplastic syndrome and acute myeloid leukemia
    Jain, Akriti G.
    Ball, Somedeb
    Aguirre, Luis
    Al Ali, Najla
    Kaldas, David
    Tinsley-Vance, Sara
    Kuykendall, Andrew
    Chan, Onyee
    Sweet, Kendra
    Lancet, Jeffrey E.
    Padron, Eric
    Sallman, David A.
    Komrokji, Rami
    HAEMATOLOGICA, 2024, 109 (07) : 2157 - 2164
  • [46] Therapy-related myelodysplastic syndrome and acute myeloid leukemia following treatment of acute myeloid leukemia: Possible role of cytarabine
    Arana-Yi, Cecilia
    Block, AnneMarie W.
    Sait, Sheila N.
    Ford, Laurie A.
    Barcos, Maurice
    Baer, Maria R.
    LEUKEMIA RESEARCH, 2008, 32 (07) : 1043 - 1048
  • [47] Compassionate use of glasdegib in combination with low-dose cytarabine for relapsed, refractory acute myeloid leukemia or high-risk myelodysplastic syndrome
    Márcio Tavares
    Sérgio Chacim
    José Mário Mariz
    Annals of Hematology, 2021, 100 : 837 - 839
  • [48] Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
    Jorge E. Cortes
    Florian H. Heidel
    Andrzej Hellmann
    Walter Fiedler
    B. Douglas Smith
    Tadeusz Robak
    Pau Montesinos
    Daniel A. Pollyea
    Pierre DesJardins
    Oliver Ottmann
    Weidong Wendy Ma
    M. Naveed Shaik
    A. Douglas Laird
    Mirjana Zeremski
    Ashleigh O’Connell
    Geoffrey Chan
    Michael Heuser
    Leukemia, 2019, 33 : 379 - 389
  • [49] Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
    Cortes, Jorge E.
    Heidel, Florian H.
    Hellmann, Andrzej
    Fiedler, Walter
    Smith, B. Douglas
    Robak, Tadeusz
    Montesinos, Pau
    Pollyea, Daniel A.
    DesJardins, Pierre
    Ottmann, Oliver
    Ma, Weidong Wendy
    Shaik, M. Naveed
    Laird, A. Douglas
    Zeremski, Mirjana
    O'Connell, Ashleigh
    Chan, Geoffrey
    Heuser, Michael
    LEUKEMIA, 2019, 33 (02) : 379 - 389
  • [50] Compassionate use of glasdegib in combination with low-dose cytarabine for relapsed, refractory acute myeloid leukemia or high-risk myelodysplastic syndrome
    Tavares, Marcio
    Chacim, Sergio
    Mariz, Jose Mario
    ANNALS OF HEMATOLOGY, 2021, 100 (03) : 837 - 839
12345